Medacta Group SA (MOVE) AI Stock Analysis

• Market Cap: $2.94B
• Dividend Yield: 0.46%
• Average Volume (3M): 12.11K
• Price to Earnings (P/E): 32.8
• Beta (1Y): 1.09
• Revenue Growth: 16.59%
• EPS Growth: 65.76%
• Country: CH
• Employees: 1,907
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): 2.84
• Shares Outstanding: 20,000,000
• 10 Day Avg. Volume: 12,204
• 30 Day Avg. Volume: 12,105
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 4.89
• Enterprise Value/Gross Profit: 7.22
• Enterprise Value/Ebitda: 17.97
• 1Y Price Target: $157.75
• Price Target Upside: 5.87% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 73 Outperform
• Price Target: CHF159.00 ▲(6.71% Upside)

Medacta Group SA's strong financial performance and positive earnings call are the primary drivers of its stock score. The company's robust revenue growth and profitability improvements are significant strengths. However, the stock's high valuation and technical indicators suggest caution. The company's ability to manage costs and maintain growth will be crucial moving forward.

Positive Factors

Financial Performance

Medacta released full fiscal year results that delivered a ~4% beat on Adjusted EBITDA, indicating strong financial performance.

Growth Strategy

Medacta outlined a comprehensive growth strategy at their first CMD that hits the right notes around the current product opportunity set, execution and deliverable targets, and capital deployment.

Negative Factors

Capital Expenditure

Operational free cash flow increased by 42%, indicating strong cash flow generation, even as capital expenditure rose, showing client traction in new product lines.

Medacta Group SA Business Overview & Revenue Model

Company Description

Medacta Group SA is a Swiss-based medical technology company specializing in innovative orthopedic solutions and surgical techniques. The company operates primarily in the orthopedic sector, focusing on hip, knee, and spinal implants, as well as associated surgical instruments and digital solutions. Medacta is recognized for its commitment to enhancing patient outcomes through cutting-edge technology and education for healthcare professionals.

How the Company Makes Money

Medacta generates revenue primarily through the sale of orthopedic implants and surgical instruments used in hip, knee, and spinal surgeries. Their revenue model relies on direct sales to hospitals and surgical centers, as well as partnerships with distributors worldwide. Key revenue streams include the sales of their proprietary products, which often come with unique features that differentiate them in the market, such as minimally invasive surgical techniques and personalized surgical planning tools. Additionally, Medacta invests in education and training programs for surgeons, which may create loyalty and long-term relationships leading to repeat sales. Strategic partnerships with healthcare providers and participation in global healthcare conferences also contribute to brand visibility and market penetration, further enhancing their earnings potential.

Medacta Group SA Financial Statement Overview

Summary

Medacta Group SA exhibits strong financial health with impressive revenue growth and profitability improvements. The balance sheet is stable with manageable leverage and improved equity returns. However, while cash flow from operations is strong, high capital expenditures limit free cash flow. A focus on optimizing capital expenditures could enhance liquidity and financial flexibility.

Income Statement

Medacta Group SA has shown strong revenue growth from 2023 to 2024, with a revenue growth rate of 15.61%. The gross profit margin remains robust at 67.6% for 2024, reflecting efficient cost management and product pricing. Net profit margin improved to 12.34%, indicating enhanced profitability. Both EBIT and EBITDA margins have increased to 15.38% and 27.18% respectively, showcasing strong operational performance. Overall, the income statement indicates healthy growth and profitability.

Balance Sheet

The company's balance sheet demonstrates solid equity growth, with a rise in stockholders' equity from 2023 to 2024. The debt-to-equity ratio remains stable at 0.64, suggesting manageable leverage. Return on equity improved to 19.2%, indicating efficient use of equity to generate profits. The equity ratio stands at 47.92%, reflecting a balanced capital structure. While leverage is within a comfortable range, continued monitoring is advised to maintain financial stability.

Cash Flow

Operating cash flow has increased significantly to 107.1M in 2024, reflecting strong cash generation capabilities. However, free cash flow remains low at 2.45M due to high capital expenditures, potentially impacting liquidity. The operating cash flow to net income ratio is robust at 1.47, indicating effective conversion of profits into cash. The free cash flow to net income ratio is weak at 0.03, suggesting limited cash availability for discretionary uses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	590.58M	510.78M	437.12M	363.13M	302.49M
Gross Profit	399.44M	347.85M	305.26M	261.25M	214.26M
EBITDA	160.51M	119.64M	106.96M	97.81M	81.96M
Net Income	72.89M	47.36M	46.25M	51.52M	37.09M
Balance Sheet
Total Assets	792.18M	695.87M	584.49M	489.27M	441.94M
Cash, Cash Equivalents and Short-Term Investments	31.59M	20.79M	32.26M	20.40M	48.07M
Total Debt	241.21M	201.98M	170.25M	132.66M	150.00M
Total Liabilities	412.51M	365.83M	309.83M	262.87M	277.22M
Stockholders Equity	379.66M	330.04M	274.65M	226.40M	164.72M
Cash Flow
Free Cash Flow	2.45M	-7.09M	10.35M	7.57M	32.31M
Operating Cash Flow	107.14M	75.13M	73.51M	54.06M	59.59M
Investing Cash Flow	-98.87M	-80.61M	-65.11M	-52.04M	-34.19M
Financing Cash Flow	4.33M	-10.13M	3.44M	-31.21M	-6.03M

Medacta Group SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 149.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOVE, the sentiment is Positive. The current price of 149 is above the 20-day moving average (MA) of 148.43, above the 50-day MA of 143.64, and above the 200-day MA of 128.97, indicating a neutral trend. The MACD of -0.36 indicates Positive momentum. The RSI at 52.30 is Neutral, neither overbought nor oversold. The STOCH value of 39.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:MOVE.

Medacta Group SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MOVE	73 Outperform	$2.94B	32.78	23.83%	0.46%	16.59%	65.76%
STMN	68 Neutral	CHF15.14B	38.54		1.00%	4.49%	45.08%
Sector *	51 Neutral	$7.93B	-0.32	-43.43%	2.21%	22.30%	-1.88%
CSBTF	―	$1.15B	―	-7.82%	―	―	―
TCHBF	―	$2.52B	34.71	4.57%	1.89%	―	―
0QLQ	―	CHF5.57B	63.71	13.49%	0.54%	―	―
MED	61 Neutral	CHF1.25B	282.78		―	7.29%	-112.70%

Medacta Group SA Corporate Events

Medacta Group SA Reports Strong H1 2025 Results with 19.8% Revenue Growth

Medacta Group SA reported a significant increase in its adjusted EBITDA margin to 29.6% in the first half of 2025, with revenues reaching €344.1 million, a 19.8% rise in constant currency. The company’s growth was driven by innovations across all business lines, including the launch of new products like the NextAR Rod Optimizer and MyImplant for Hip, as well as the acquisition of Parcus Medical, which expanded its sports medicine portfolio. Medacta’s strategic initiatives and expansion efforts have positioned it for continued success, with notable revenue growth in key regions such as North America and Asia Pacific, and across all product lines, particularly in knee and extremities.

The most recent analyst rating on (CH:MOVE) stock is a Hold with a CHF151.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.

Medacta Group SA Reports Strong H1 2025 Revenue Growth and Upgrades Guidance

Medacta Group SA reported a significant revenue growth of 19.8% in constant currency for the first half of 2025, reaching Euro 344.1 million. This growth was driven by substantial performance across all business lines and geographic markets, with notable increases in the Asia Pacific and North America regions. The company also upgraded its full-year and mid-term guidance, reflecting its strong market position and successful integration of Parcus Medical, which contributed to the revenue increase. Medacta’s focus on innovative solutions and medical education continues to bolster its industry standing and offers promising implications for stakeholders.

The most recent analyst rating on (CH:MOVE) stock is a Buy with a CHF160.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.